The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Allergy/Immunology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Sun, 20 Sep 2026 10:08:11 GMT 2026 NEJM Group en-us 1440 Among infants with a family history of allergy, a maternal diet high in eggs and peanuts during pregnancy and lactation did not result in a lower risk of egg or peanut allergy at 1 year than a standard diet. https://www.nejm.org/doi/full/10.1056/NEJMoa2605659?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605659 Debra J. Palmer, Dianne E. Campbell, Ralph Nanan, Peter S. Hsu, Anita M. Jorgensen, Michael O’Sullivan, Merryn J. Netting, Vicki McWilliam, Susan L. Prescott, Michael S. Gold, Kirsten P. Perrett, Maria Makrides, Thomas R. Sullivan 2026-09-17 Trial of a Maternal Diet Rich in Eggs and Peanuts to Reduce Infant Allergy Food-allergy prevention has undergone a major conceptual shift over the past decade. After years in which avoidance of allergenic foods during infancy, and sometimes during pregnancy and lactation, was considered to be a biologically plausible strategy to prevent food allergy, randomized trials of early infant feeding changed practice by showing... https://www.nejm.org/doi/full/10.1056/NEJMe2610158?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2610158 Maria C. Jenmalm 2026-09-17 Maternal Allergen Consumption and Infant Food Allergy — Reassurance, Not Prescription In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. https://www.nejm.org/doi/full/10.1056/NEJMoa2602678?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602678 Fernando C. Fervenza, Fan Fan Hou, Chuan-Ming Hao, Gianna M. Kirsztajn, Loreto Gesualdo, Tomasz Hryszko, Antonio Pisani, Dario Roccatello, Andrew S. Bomback, Julie Rae, Farima Barmaki, Eriola Berisha, Thomas Schindler, Theodore A. Omachi, Jay P. Garg, Ana Malvar, the MAJESTY Trial Investigators* 2026-09-10 Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy A 65-year-old man was admitted to this hospital because of fever, intermittent abdominal pain, and rash. The fever began 5 weeks earlier, and palpable purpura developed 1 week before admission. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2517855?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2517855 Jacqueline T. Chu, Robert G. Rasmussen, Jacquelyn M. Nestor, Mack Y. Su 2026-09-10 Case 25-2026: A 65-Year-Old Man with Fever and Rash Membranous nephropathy, the leading cause of nephrotic syndrome in adults, is generally diagnosed through a kidney biopsy in patients presenting with heavy proteinuria, hypoalbuminemia, and edema. Its diagnostic hallmarks include subepithelial immune-complex deposition along the outer aspect of the glomerular basement membrane, which leads to diffuse capillary-wall thickening and a... https://www.nejm.org/doi/full/10.1056/NEJMe2609719?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2609719 María José Soler 2026-09-10 A Step Forward — Obinutuzumab for Membranous Nephropathy Trichodysplasia spinulosa–associated polyomavirus was identified as a likely cause of neuroinvasive infection in a 16-year-old patient who had undergone renal transplantation. https://www.nejm.org/doi/full/10.1056/NEJMc2602730?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2602730 Aaron Bodansky, Natalie Pierson, Venice Servellita, Kaitlin Marquis, Robert Valdovinos, Nahid Hiermandi, Andrew W. Bollen, Ilay Caliskan, Kanish Mirchia, Charles Omura, Jessica Streithorst, Brian LaFranchi, Timothy J. Henrich, Chung-Yu Wang, Bryan Castillo-Rojas, William Bernal, Alexandra Bicki, Erica Winnicki, Marsha Lee, Kelsey Zorn, Sukhman Sidhu, Orit Glenn, Mary Karalius, Matt S. Zinter, Kendall Nash, Michael R. Wilson, Thomas M. Tarro, Joseph L. DeRisi, Charles Y. Chiu 2026-09-10 Neuroinvasive Trichodysplasia Spinulosa–Associated Polyomavirus Infection For more than 25 years, narcolepsy type 1 (formerly narcolepsy with cataplexy) has been known to be associated with a deficiency of orexin within cerebrospinal fluid (CSF) and reduced staining of orexin-containing hypothalamic neurons on autopsy.1 Subsequent work has led to the current understanding of narcolepsy type 1... https://www.nejm.org/doi/full/10.1056/NEJMe2607491?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2607491 Lynn Marie Trotti 2026-09-09 Targeted Treatment for Narcolepsy Type 1 Drs. Yanagisawa and Mignot received the 2026 Albert Lasker Award for Basic Medical Research for their pivotal work in the discovery of the orexin (hypocretin) system and its role in narcolepsy. https://www.nejm.org/doi/full/10.1056/NEJMcibr2608811?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2608811 Sebastiaan Overeem, Birgitte R. Kornum 2026-09-09 The Legacy of Orexin (Hypocretin) Research in Narcolepsy and Beyond In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2606998?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606998 Frank C. Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens, Fernando J. Martinez, Jinping Zheng, Maarten van den Berge, Matteo Bonini, MeiLan K. Han, Dave Singh, Gerard J. Criner, Christopher E. Brightling, Alberto Papi, Surya P. Bhatt, Martin Jenkins, Marta Mikosz, Piotr Chołbiński, Monika Ziemiecka, Magnus Löfdahl, Deepa Arya, Madhavi Yadavalli, Bryan H. Brodek, Malin Fagerås, Samuel Bardsley, Neil Martin, Rajesh Patel, Ioannis Psallidas, the OBERON and TITANIA Trial Investigators* 2026-09-08 Tozorakimab to Prevent COPD Exacerbations A 33-year-old man with systemic lupus erythematosus presented with pruritic, burning plaques that evolved into urticarial lesions. Skin biopsy revealed papillary dermal edema, intravascular neutrophils, and C3 deposition. https://www.nejm.org/doi/full/10.1056/NEJMicm2602968?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2602968 Arjun Mahajan, Evan W. Piette 2026-09-03 Urticarial Vasculitis Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. https://www.nejm.org/doi/full/10.1056/NEJMc2603114?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2603114 Yu-Hang Cheng, Ke Shang, Chuan Qin, Ming-Hao Dong, Yun-Hui Chu, Ke Huang, Zhi-Cheng Mei, Jun Xiao, Zi-Hao Liang, Yu-Hang Li, Wei Wang, Dai-Shi Tian 2026-09-03 Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders Azithromycin did not lead to a greater reduction in symptom severity than placebo among preschool children presenting to the ED with wheezing, regardless of whether they tested positive for pathogenic bacteria. https://www.nejm.org/doi/full/10.1056/NEJMoa2516505?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516505 Kurt R. Denninghoff, T. Charles Casper, Joseph J. Zorc, Richard M. Ruddy, Sarah Satola, Wendi-Jo Wendt, Claudia R. Morris, Melissa M. Tavarez, Matthew J. Lipshaw, Maria Y. Kwok, Jo-Ann O. Nesiama, Kyle A. Nelson, Michael Webb, Fernando D. Martinez, the PECARN AZ-SWED Trial Study Group* 2026-08-20 Azithromycin for Preschoolers with Wheezing in the Emergency Department This review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification. https://www.nejm.org/doi/full/10.1056/NEJMra2507867?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2507867 Isabelle Plo, William Vainchenker 2026-08-20 Myeloproliferative Neoplasms A 74-year-old man with myasthenia gravis was evaluated for dyspnea, proximal muscle weakness, hypoxemia, and a painful tongue lesion. Medications included prednisone and mycophenolate mofetil. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2603179?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2603179 Pierre O. Ankomah, Cynthia L. Czawlytko, Joseph B. El Khoury, Stefen Andrianus, M. Lauren Donnelly-Morell 2026-08-20 Case 24-2026: A 74-Year-Old Man with Dyspnea, Proximal Muscle Weakness, and Hypoxemia A 73-year-old woman with rheumatoid arthritis and a 10-month history of pantoprazole therapy presented with skin lesions on her torso. Annular polycyclic lesions were observed on her upper back. https://www.nejm.org/doi/full/10.1056/NEJMicm2605381?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2605381 Norbertus A. Ipenburg, Tobias E. Sangers 2026-08-20 Drug-Induced Subacute Cutaneous Lupus Erythematosus Acute wheezing attacks are common in preschool-age children. These attacks lead to impaired quality of life1 and are associated with trajectories of poor lung function that may be lifelong, especially in children who are exposed to tobacco smoke and have allergic sensitization.2 Despite increased focus on... https://www.nejm.org/doi/full/10.1056/NEJMe2606675?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606675 Andrew Bush, Sejal Saglani 2026-08-20 No to Azithromycin for Preschoolers with Acute Wheezing in the Emergency Department A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. https://www.nejm.org/doi/full/10.1056/NEJMc2604408?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604408 Per-Ola Carlsson, Xiaomeng Hu, Hanne Scholz, Torbjörn Lundgren, Sofie Ingvast, Tim Scholz, Olof Eriksson, Per Liss, Irina Velikyan, Di Yu, Grigol Tediashvili, Tobias Deuse, Olle Korsgren, Sonja Schrepfer 2026-08-20 Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression Among 14 pregnancies in 13 patients with autoimmune disease who had undergone CAR T-cell therapy, early maternal and neonatal outcomes appeared reassuring, with no disease relapses reported and 8 healthy infants born to date. https://www.nejm.org/doi/full/10.1056/NEJMc2607737?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2607737 Georg Schett, Andreas Wirsching, Tobias Rothe, Vanessa Visconti, Neil Kramer, Markus Metzler, Tobias Krickau, Gregory W. Kirschen, Daphne Landau, Caitlin Elgarten, Vikas Majithia, Ellen De Langhe, Peter Vandenberghe, Britta Maurer, Zahir Amoura, David Simon, Gerhard Krönke, Peter Gergely, Melissa Fernandes, Tamas Shisha, Brandon M. Law, Ashley Koegel, David J. Chang, Andreas Mackensen, Fabian Müller, Melanie Hagen 2026-08-20 Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2602567?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602567 John H. Stone, Frank Buttgereit, Alain Saraux, Wolfgang A. Schmidt, Christian Dejaco, Robert Spiera, Bhaskar Dasgupta, Edit Drescher, Andrew Jordan, Libor Novosad, Daiki Nakagomi, Yoshinobu Koyama, Sergio Duran-Barragan, Gerald Tracey, Adeline Ruyssen-Witrand, Andrea Rubbert Roth, Juanzhi Fang, Jennifer Ng, Renuka Hiremath, Roselyne Raffner, Ruvie Martin, Silvia Napoletano, Songqiao Huang, Julian Storim, Manmath Patekar, the REPLENISH Investigators* 2026-08-13 Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica Since Dr. Phillip Hench reported on the efficacy of glucocorticoids for rheumatoid arthritis in 1949, glucocorticoids have saved many lives and have offered relief to countless patients. Glucocorticoids have been used as the mainstay of treatment for many immune-mediated inflammatory diseases, including polymyalgia rheumatica and giant-cell arteritis (GCA), owing to... https://www.nejm.org/doi/full/10.1056/NEJMe2605851?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605851 Yoshiya Tanaka 2026-08-13 Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting